Changing lives with plant-based medicines

We are a bio-pharma company utilising the medical value of phytocannabinoids to provide relief to people suffering across the globe.

Creating the future of medicine from natural ingredients

Our goal is to provide cost effective, standardised, affordable medicines. We are leaders in the conceptualisation, formulation and creation of products that are consistent, regulation compliant, plant-derived medicines. We want to perfect the pathway from nature to medicine through a robust clinical pipeline.

Plant-based medicines to treat

Epilepsy

Epilepsy

CBD-THC products have been shown to be safe and efficacious in real world settings when used to control seizures that could not be effectively managed by standard medical treatments.

Dementia

Dementia

Phytocannabinoid derived IMP’s are currently in clinical development for the management of BPSD (Behavioural and Psychological Symptoms in Dementia) based on real world data which supports the potential for this implementation.

COVID-19

COVID-19

Natural based ingredients such as Curcumin, Boswellia serrata, Artemisinin and Vitamin C, have demonstrated their effectiveness during Stage II clinical trials and serve to modulate inflammatory / immune markers associated with the COVID-19 virus.

Cancer

Cancer

Clinical experience supports the use of various cannabinoid-based formulations for the amelioration of a range of diseases and the treatment of related symptoms. These include various types of pain, pruritus (itching), sleep disorders, poor appetite, anxiety and more.

Crohn's Disease

Crohn's Disease

Cannabinoids, such as those made available in MGC products, have been used both historically and in recent times, with particular success in Crohn’s disease for the management of symptoms such as pain, loss of appetite, and diarrhoea.

Cerebral Palsy

Cerebral Palsy

Clinical experience corroborates the evidence-based use of cannabinoids for the management of seizures and spasticity, both of which have a substantial impact on the lives of those affected by cerebral palsy as well as their caretakers and families.

CBD-THC products have been shown to be safe and efficacious in real world settings when used to control seizures that could not be effectively managed by standard medical treatments.
Phytocannabinoid derived IMP’s are currently in clinical development for the management of BPSD (Behavioural and Psychological Symptoms in Dementia) based on real world data which supports the potential for this implementation.
Natural based ingredients such as Curcumin, Boswellia serrata, Artemisinin and Vitamin C, have demonstrated their effectiveness during Stage II clinical trials and serve to modulate inflammatory / immune markers associated with the COVID-19 virus.
Clinical experience supports the use of various cannabinoid-based formulations for the amelioration of a range of diseases and the treatment of related symptoms. These include various types of pain, pruritus (itching), sleep disorders, poor appetite, anxiety and more.
Cannabinoids, such as those made available in MGC products, have been used both historically and in recent times, with particular success in Crohn’s disease for the management of symptoms such as pain, loss of appetite, and diarrhoea.
Clinical experience corroborates the evidence-based use of cannabinoids for the management of seizures and spasticity, both of which have a substantial impact on the lives of those affected by cerebral palsy as well as their caretakers and families.
We are just scratching the surface of where plant-based treatments, intersected with modern science, will bring us back to balanced global health

Dr. Jonathan Grunfeld

VP Medical Innovation
Suffering from chronic back pain for over 15 years I have struggled to maintain effective sleep due to constantly tossing and turning to get comfortable. Using MP1:1 25mg/ml CBD 25mg/ml THC not only helps with my pain, but it also relaxes my body and ensures that my sleep patterns are more consistent.

Patient

Australia
I was diagnosed with Shingles a few years ago and after being in constant pain I was advised to try CBD Oil. After trying a few different products, I decided to try MGC’s CannEpil and I have found that it has helped to reduce the severe headaches I was suffering from and made life so much brighter.

Patient

Australia

Our Partners and Collaborators

We partner with leading institutions, companies and groups worldwide, to support expanding the agenda of plant-based medicines supporting unmet needs.

Research, Clinical and Academia

Education & Patient Access Partners

Distribution, Logistics, Manufacturing

Leading the global shift towards plant-based, naturally harmonious medicines, improving lives and public health.

MGC Pharma’s phase III clinical trial has been designed to evaluate the efficacy and safety of CimetrA™ as a treatment for hospitalised patients diagnosed with COVID-19, and to provide additional data for claims on the product as an Investigational Medicinal Product (IMP). The trial will enrol a total of 252 patients and will be conducted over a 28-day period.

The Israeli Ministry of Health approval has now been received and the trial will shortly be initiated at the two clinical sites, Rambam Health Care Campus and Nazareth Hospital EMMS in Israel. This follows receipt of ethics committee approval in March 2021 (see ASX announcement 23 March 2021).

Interim results of the trial were expected to be released in August 2021. However, the Company is currently enrolling patients into a Phase IIb Dosing Study for CimetrA, which aims to determine the optimum dosage of CimetrA to treat
patients suffering from COVID-19, with these results to inform the dosage used in the Phase III trial. 

Once enrolments into the Phase III trial recommence, the company intends to expand this trial to strategic global jurisdictions.

Artemic

ArtemiC was tested for safety and efficacy in a double-blind, placebo-controlled clinical trial involving 50 patients diagnosed with COVID-19.

In a Phase II clinical trials, ArtemiC statistically improved the recovery of patients infected with COVID-19. All patients had a confirmed COVID-19 infection, were hospitalized in a stable, moderate condition and were between the ages of 40 and 75. By the end of the two-week trial, 100% of the patients in the treatment group had shown improvement.

Within 15 days of follow-up, all had fully recovered. No patients in the treatment group required additional medical intervention and no adverse reactions to the treatment were recorded.

Those who were treated with ArtemiC showed:

  • 100% met all FDA primary and secondary end points
  • Improved clinical recovery
  • Improvement of symptoms and pain
  • Faster overall recovery time
  • No requirement for additional medical assistance (ICU, ventilation

CogniCann® – Phase II clinical trial
The Phase II clinical trial at the University of Notre Dame in Perth, Western Australia has been designed to evaluate the potential behavioral benefits of CogniCann® on patients with dementia and Alzheimer’s disease. The trial will enrol 50 patients and is expected to last until Q2 2022.

Initial recruitment commenced in January 2020 but was temporarily suspended due to the COVID-19 restrictions in WA. Recruit has recommenced and 21 patients have been enrolled in the trial over the last three months. Interim results are expected to be released in Q2 2022.

All three trials are well funded, following the successful £6.5 million IPO fundraising and listing on the London Stock Exchange in February 2021, and the Company will make further updates on them in due course.

CannEpil® (MGCND00EP1) – Phase IIb randomised, double blind, placebo controlled clinical study.

The phase IIb clinical trial will take place at the Schindler Hospital in Israel and will focus on the safety and efficacy of CannEpil® as an add-on treatment in children and adolescents with treatment resistant epilepsy, also known as refractory epilepsy. A total of more than 100 patients will be recruited into the trial.

The study drug import process has commenced following Israeli Ministry of Health approval. The trial will be initiated in July and the first patient is expected to be enrolled in June 2022. Interim results of the trial are expected in Q4 2022.

MGC has already initiated a Driving Safety study of CannEpil® in Australia following the reopening of universities after the COVID-19 lockdowns. This trial involves healthy volunteers and aims to demonstrate the safety of CannEpil® in order to provide supportive data to the regulatory authorities.

Rob Clements

Chief Commercial Officer

After starting his career with an initial spell in the City of London Rob joined the pharmaceutical industry in 1991. Over the following decade he progressed rapidly through field roles to Marketing Management. He then established his own consultancy specialising in relationship marketing and product launch for healthcare companies.

He subsequently worked in business development roles identifying potential product acquisitions – both prescription and OTC – the development and launch of medical devices and general strategic functions. His roles included improving business performance and company morale, and oversight of companies’ core marketing of ethical brands.

From 2011 Rob headed a pan-national team for Forest Laboratories delivering new ethical products to markets alongside management of the existing portfolio. As Director both of Marketing and Commercial operations he was also directly responsible for budgeting, planning and data provision, whilst remaining closely involved with the assessment of BD opportunities.

An expert in specialist disease marketing and business development Rob has also worked extensively on a number of proposed private equity asset buyouts in addition to previous consultancy work.

From 2019 he worked with Healthcare at Home (now Sciensus Rare) to help establish an international rare medicines division. As Vice President of Business Development his role included ongoing development and refinement of the service offering and building new business opportunities; from strategic partnerships and potential MA acquisitions through to establishing Sciensus Rare’s global footprint.